𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cystic fibrosis-associated liver disease (CFALD): what is the risk?

✍ Scribed by William F. Balistreri

Book ID
116682959
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
51 KB
Volume
145
Category
Article
ISSN
1097-6833

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Noncirrhotic presinusoidal portal hypert
Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis–associated liver disease
✍ Peter Witters; Louis Libbrecht; Tania Roskams; Kris De Boeck; Lieven Dupont; Mar πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 632 KB

Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.